Not Yet Recruiting PHASE3 NCT06440824
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Sponsor: Shandong University
Conditions
CTIT-Chemotherapy Induced Thrombocytopenia
Interventions
Recombinant Human Thrombopoietin Romiplostim N01
Updated 2 times since 2024 Last updated: Jun 3, 2024 Started: Jun 1, 2024 Primary completion: Jun 1, 2025 Completion: Nov 30, 2025
A PHASE3 clinical study on CTIT-Chemotherapy Induced Thrombocytopenia, this trial is actively recruiting participants. The trial is conducted by Shandong University and has accumulated 2 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Sep 2024 — Present [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shandong University
Data source: Shandong University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.